Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Prostate Cancer Treatment with Mitoxantrone

Prostate Cancer Treatment with Mitoxantrone

What is mitoxantrone, and how does it work?

Cancerous tumors, unlike normal tissue, are characterized by uncontrolled cell division. Normal cells stop dividing when they come into contact with similar cells; this mechanism is known as contact inhibition. Cancer cells lose this ability. Cancer cells do not have the normal checks and balances that control and limit cell division. Cell division takes place through the cell cycle in both normal and cancer cells. The cell cycle proceeds from a resting phase to active growth phases, followed by mitosis (division).

Chemotherapy's ability to kill cancer cells depends on its ability to stop cell division. The drugs generally work by damaging RNA or DNA, which tells the cell how to copy itself by dividing. If cells cannot divide, they die. The faster cells divide, the more likely chemotherapy is to kill the cells and cause the tumor to shrink. The drugs also cause cell suicide (self-destruction, or apoptosis).

Chemotherapy drugs that affect cells only while they are dividing are called cell-cycle-specific anticancer agents. Chemotherapy drugs that affect cells while they are resting are called cell-cycle-nonspecific. Chemotherapy scheduling is determined by the cell type, the rate of division, and when a particular drug may be effective. Chemotherapy is therefore generally given in cycles.

Mitoxantrone is classified as an antitumor antibiotic. Antitumor antibiotics are made from natural products produced by the soil fungus Streptomyces. These drugs act during many phases of the cell cycle and are considered cell-cycle-specific. There are several types of antitumor antibiotics:

  • Anthracyclines: Doxorubicin, Daunorubicin, Mitoxantrone, and Idarubicin.
  • Chromomycins: Dactinomycin and Plicamycin.
  • Others: Mitomycin and Bleomycin.

For which cancers and purposes is mitoxantrone used?

Mitoxantrone is an anticancer ("antineoplastic" or "cytotoxic") chemotherapy drug. Mitoxantrone is classified as an "antitumor antibiotic." It is used for the following conditions:

  • In patients with advanced prostate cancer that does not respond to hormone therapy, in combination with steroids
  • Acute myelogenous leukemia (AML)
  • Breast cancer
  • Non-Hodgkin lymphoma

Purpose of treatment

It is used to bring the disease under control by reducing it, extend survival, and reduce disease-related symptoms.

Mitoxantrone administration, dose, and schedule

Mitoxantrone is administered at 12 mg/m2 in a cycle every 21 days.

In addition to treatment, patients regularly take 8 mg of dexamethasone every morning and 40 mg of famotidine every evening during the treatment period.

Mitoxantrone is administered over 30 min as a free intravenous infusion (drip).

It is generally administered in day-care chemotherapy units, where patients return home after treatment.

Depending on the response to treatment and tolerability, a maximum total of 200 mg may be administered over the course of treatment.

Mitoxantrone side effects

The following side effects are common in patients receiving mitoxantrone (occurring in more than 30%):

The following side effects are less common in patients receiving mitoxantrone (occurring in approximately 10-29%):

  • Fatigue
  • Mouth sores
  • Hair loss
  • Diarrhea
  • Abnormal ECG, abnormal heart rhythms (arrhythmia)
  • Low blood pressure.
  • Blue / green discoloration of the whites of the eyes or urine for 1-2 days after treatment.

Potential late-onset side effects of Mitoxantron:

A serious but rare side effect of mitoxantrone may affect the heart's pumping ability. Before you receive Mitoxantron, your doctor may check your heart function and will monitor your heart periodically during treatment.

Years after receiving mitoxantrone, there is a very small risk of developing secondary cancers such as leukemia. Talk to your doctor about this risk.

Follow-up

How often is follow-up needed?

Blood tests are generally checked before each treatment. The necessary tests are a complete blood count and a comprehensive metabolic panel (biochemistry). Other blood tests may be added according to the physician's recommendation.

How often is imaging (radiological examination) needed?

Imaging methods such as computed tomography (CT) and/or magnetic resonance imaging (MRI), Ga-68 PSMA PET/BT are checked before treatment. They are repeated after several treatments or approximately every six weeks. Imaging may be performed earlier or later according to the physician's recommendation.

How do blood test or imaging results affect treatment?

Depending on the results, your doctor may continue mitoxantrone as planned, adjust its dose, or change the treatment.

Precautions while using mitoxantrone

  • Unless instructed otherwise, drink at least two to three liters of fluid daily.
  • Wash your hands frequently.
  • Use an electric razor to minimize the risk of bleeding.
  • Avoid contact sports or activities that could cause injury.
  • Use a soft toothbrush to help treat or prevent mouth sores.
  • Avoid sun exposure. Use SPF 15 (or higher) sunscreen and wear protective clothing.
  • In general, alcoholic drinks should be kept to a minimum or avoided altogether. You should discuss this with your doctor.
  • Get plenty of rest.
  • Maintain good nutrition.
  • If you experience symptoms or side effects, make sure to discuss them with your healthcare team. They may prescribe medication or offer other suggestions that are effective in managing these problems.

Sources

R Collins et al. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer. 2006 Aug.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Prostate Cancer Treatment with Mitoxantrone

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy